KEYTRUDA Plus Padcev Extends Survival in MIBC Trial
RAHWAY, N.J., Dec. 17, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 3 KEYNOTE-B15 (EV-304)...
perioperative immunotherapy
Advertisement
Advertisement
Advertisement
RAHWAY, N.J., Dec. 17, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 3 KEYNOTE-B15 (EV-304)...
Advertisement